Home
HelpTest ID DMTBR Mycobacterium tuberculosis Complex, Molecular Detection of Drug Resistance Markers, Next-Generation Sequencing
Ordering Guidance
This test is used to identify the drug resistance variants in an M tuberculosis complex culture isolate.
Shipping Instructions
1. For shipping information see Infectious Specimen Shipping Guidelines
2. Place specimen in a large infectious container (T146) and label as an etiologic agent/infectious substance.
Necessary Information
Specimen source and organism identification are required.
Specimen Required
Supplies: Infectious Container, Large (T146)
Specimen Type: Mycobacterium tuberculosis complex isolate growing in pure culture
Container/Tube:
Preferred: Solid slant medium (eg. Middlebrook 7H10, 7H11 or Lowenstein Jensen agar)
Acceptable: Broth medium (eg. Mycobacteria Growth Indicator Tube, 7H9 broth, BACT/ALERT MP or VersaTREK bottle). Note: Broth specimens will require subculture which will delay results.
Specimen Volume:
Solid slant medium: Isolate with visible growth
Broth medium: Greater than or equal to 3 mL of broth culture
Collection Instructions:
1. Organism must be in pure culture, actively growing. Do not submit mixed cultures.
2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.
3. Turnaround time for results may be delayed if subculture is needed to ensure purity.
Useful For
Molecular detection of drug resistance variants in culture isolates of the Mycobacterium tuberculosis complex
May provide a more rapid detection of drug resistance than phenotypic, broth-based testing for selected gene targets
Aiding in the resolution of discrepant results obtained using phenotypic methods
Testing for M tuberculosis complex isolates that are not sufficiently viable to allow for culture-based testing
Testing Algorithm
Next-Generation sequencing (NGS) of Mycobacterium tuberculosis complex isolates is performed followed by evaluation of selected genes of interest for the presence of well-characterized, drug resistance-conferring variants.
Special Instructions
Method Name
Next-Generation Sequencing (NGS)
Reporting Name
M tuberculosis drug resistance, NGSSpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Ambient (preferred) | |
| Refrigerated | ||
Reference Values
Not applicable
Day(s) Performed
Monday through Friday
Report Available
7 to 14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87153 - M tuberculosis drug resistance, NGS
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| DMTBR | M tuberculosis drug resistance, NGS | 94053-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| TBSS | Isolate from Specimen Source | 31208-2 |
| TBDI | Organism Identification | 42803-7 |
| 623237 | rpoB | 94065-0 |
| 623238 | inhA | 94055-1 |
| 623239 | fabG1 | 94056-9 |
| 623240 | katG | 94054-4 |
| 623241 | ahpC | 94057-7 |
| 623242 | ethA | 72866-7 |
| 623243 | pncA | 94059-3 |
| 623244 | embB | 94058-5 |
| 623245 | gidB | 94061-9 |
| 623246 | rpsL | 94063-5 |
| 623247 | rrs | 94062-7 |
| 623248 | eis | 94064-3 |
| 623249 | tlyA | In Process |
| 623250 | gyrA | 94060-1 |
| 623251 | gyrB | 101576-7 |
| 623252 | rrl | In Process |
| 623253 | rplC | In Process |
| 623254 | rv0678 | In Process |
| 623255 | rifampin (RIF) Interpretation | 46244-0 |
| 623256 | isoniazid (INH) Interpretation | In Process |
| 623257 | pyrazinamide (PZA) Interpretation | 46245-7 |
| 623258 | ethambutol (EMB) Interpretation | 46247-3 |
| 623259 | streptomycin (SM) Interpretation | In Process |
| 623260 | amikacin (AMI) Interpretation | In Process |
| 623261 | kanamycin (KAN) Interpretation | In Process |
| 623262 | capreomycin (CAP) Interpretation | In Process |
| 623263 | fluoroquinolones (FQ) Interpretation | In Process |
| 623264 | ethionamide (ETH) Interpretation | 72866-7 |
| 623265 | linezolid (LIN) Interpretation | In Process |
| 623266 | bedaquiline (BDQ) Interpretation | In Process |
| 623267 | clofazimine (CFZ) Interpretation | In Process |
| 623508 | Footnotes | 48767-8 |